Role of 18F-FDG PET/CT in bone and soft tissue sarcoma

Introduction: precise diagnosis and staging was required for effective management pationts. imaging techniques, such as ultrasound, computed tomography (ct), and magnetic resonance imaging (mri), are commonly used for the detection of the location, size, as well as morphological and structural changes of adjacent tissues. nonetheless, these modalities provide little information about tumor biology.objective: this study presents the experiences of a private clinical center regarding the role of f-fluorodeoxyglucose positron emission tomography/computed tomography (18f-fdg pet/ct) in the diagnosis, staging, restaging, and monitoring of treatment response in the management of patients with sarcoma.methods: the records of patients with bone and soft tissue sarcoma referred to a private specialized hospital for 18f-fdg pet/ct from 2016 to 2019 were evaluated in this study. information, such as radiotherapy, chemotherapy, and pathology of patients, was recorded.results: regarding gender, 66.7% of cases were male (mean age of 26.37 years) and 33.3% of subjects were females (mean age of 28.76 years). among suvmax reported in observed lesions, either metastasis or recurrence, and primary tumor, the highest value was observed in the lymph node on the right side of the neck due to metastasis of the giant cell tumor of the bone (suvmax = 18.23) and the lowest in the right lung pulmonary node due to the retroperitoneal sarcoma metastasis (suvmax=0.88). furthermore, the mean suvmax of the hepatic right lobe was not significantly different between diabetic and non-diabetic patients (p=0.761).conclusion: as evidenced by the obtained results, 18f-fdg pet/ct appears to be a noninvasive measurement method for the prediction of events and outcomes; nonetheless, it is currently considered an optional test, which calls for further studies to corroborate its case-effectiveness.